Premium
Functional and anatomical changes after standard and half dose verteporfin PDT in central serous choroidopathy
Author(s) -
Montero Moreno J.A.,
RuizMoreno O.,
GarciaMartinez J.,
SierraRodríguez M.A.,
RuizMoreno J.M.,
Gonzalez Uruena C.,
Calvo Perez P.,
Ruiz del Tiempo P.,
Lopez Gaona A.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0655
Subject(s) - verteporfin , medicine , nuclear medicine , macular degeneration , photodynamic therapy , ophthalmology , visual acuity , choroidal neovascularization , chemistry , organic chemistry
Purpose To report the anatomical and functional changes occurring in patients with central serous choroidopathy (CSC) treated by standard or half dose photodynamic therapy (PDT) with verteporfin. Methods Retrospective, interventional, multicenter study. The clinical files, optical coherence tomography (OCT) and autofluorescence (AF) images of patients with CSC treated by standard or half dose PDT were revised. Results A total of 152 patients were identified (111 males). Patient's mean age was 50 years (standard deviation 10, range 30–68) and the average follow‐up was 21 months (SD 12, range 3–54). Mean baseline corrected visual acuity (VA) was 64 ETDRS letters (SD 18, range 2–85) and final VA was 72 letters (SD 16, range 2–85). The average central macular thickness (CMT) determined by automated OCT software at baseline was 293 μ m (SD 85, range 115–615) and 221 μ m (SD 45, range 41–615) by the end of follow up. Eighty‐two patients were treated by standard, full dose PDT and 70 patients were treated by half dose verteporfin PDT. The average number of required PDT sessions was 1.13 (SD 0.47, range 1–4) for standard PDT vs. 1.30 (SD 0.52, range 1–3) for half dose PDT (p = 0.009; Student's t test for unpaired data). Both groups did not differ in terms of age, previous lapse since diagnosis, baseline VA, final VA, and final CMT (p = 0.72; p = 0.18; p = 0.41; p = 0.30; p = 0.85; Student's t test for unpaired data). However, they differed in terms of basal CMT (mean CMT in the standard PDT group was 320 vs. 262 μ m for the half dose group). The PDT laser spot could not be observed in the AF images in any of the groups. Conclusions According to our findings, standard, full dose PDT provides similar visual outcomes as half dose verteporfin PDT with a lower rate of re treatments and no differences in CMT or AF patterns.